For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome

Hello. We're improving abcam.com and we'd welcome your feedback.

Hello. We're improving abcam.com and we'd welcome your feedback.

Infomation icon

We haven't added this to the BETA yet

New BETA website

New BETA website

Hello. We're improving abcam.com and we'd welcome your feedback.

Take a look at our BETA site and see what we’ve done so far.

Switch on our new BETA site

Now available

Search and browse selected products

  • A selection of primary antibodies

Purchase these through your usual distributor

In the coming months

  • Additional product types
  • Supporting content
  • Sign in to your account
  • Purchase online
United States
Your country/region is currently set to:

If incorrect, please enter your country/region into the box below, to view site information related to your country/region.

Call (888) 77-ABCAM (22226) or contact us
Need help? Contact us

  • My account
  • Sign out
Sign in or Register with us

Welcome

Sign in or

Don't have an account?

Register with us
My basket
Quick order
Abcam homepage

  • Research Products
    By product type
    Primary antibodies
    Secondary antibodies
    ELISA and Matched Antibody Pair Kits
    Cell and tissue imaging tools
    Cellular and biochemical assays
    Proteins and Peptides
    By product type
    Proteomics tools
    Agonists, activators, antagonists and inhibitors
    Cell lines and Lysates
    Multiplex miRNA assays
    Multiplex Assays
    By research area
    Cancer
    Cardiovascular
    Cell Biology
    Epigenetics
    Metabolism
    Developmental Biology
    By research area
    Immunology
    Microbiology
    Neuroscience
    Signal Transduction
    Stem Cells
  • Customized Products & Partnerships
    Customized Products & Partnerships

    Customized products and commercial partnerships to accelerate your diagnostic and therapeutic programs.

    Customized products

    Partner with us

  • Support
    Support hub

    Access advice and support for any research roadblock

    View support hub

    Protocols

    Your experiments laid out step by step

    View protocols

  • Events
    • Conference calendar
    • Cancer
    • Cardiovascular
    • Epigenetics & Nuclear signaling
    • Immunology
    • Neuroscience
    • Stem cells
    • Tradeshows
    • Scientific webinars
    Keep up to date with the latest events

    Full event breakdown with abstracts, speakers, registration and more

    View global event calendar

  • Pathways
    Cell signalling pathways

    View all pathways

    View all interactive pathways

Explore the power of knock-out cell lines for your research

Histone H3 mutations in cancer

Related

  • Histone modifications
    • Histone modifications antibodies
      • HDAC antibodies
      • Cancer epigenetics guide
        • Cancer epigenetics poster
          • Epigenetics application guide
            • Chromatin accessibility
              • ChIP guide
                • DNA methylation
                  • RNA modifications
                    • Epigenetic modifications poster
                      • Polycomb and chromatin remodeling resources
                        • Guide to chromatin remodeling complexes
                          • Chromatin remodeling research tools

                            ​​Advance your research on histone mutations in cancer with our recombinant monoclonal RabMAbs antibodies and find the best target for your studies.

                            ​Published August 28, 2020

                            Contents

                            • The role of histone mutations in cancer
                            • Tools to study your target
                            • Explore our histone H3 mutant panels
                            • References

                            The role of histone mutations in cancer​

                            ​​​​​​Besides chromatin-associated or regulatory proteins, histone proteins themselves can be mutated in cancers. Recurrent histone mutations have been recently described in various cancer types, including brain tumors, chondroblastoma, giant cell tumors of bone, and leukemia. Histone mutations are often heterozygous and frequently comprise single amino acid substitutions in the tails of histone variants. They are also somatic single-gene mutations that arise at high frequencies in particular diseases.

                            The somatic mutations are frequently found in histone 3 (H3), with substitutions of methionine to lysine on H3.3K27 and H3.3K36 being the most common alterations. Here we review key five histone mutations affecting H3 - H3K27M, H3K36M, H3G34 (W/V/R) - and their role in cancer.

                            H3K27M

                            Although H3K27M mutations (Figure 1) are mainly associated with pediatric brain tumors, such as pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine glioma (DIPG), they have also been identified in adult cancers, including acute myeloid leukemia, melanoma, and glioma1. H3K27M mutations have been shown to suppress the methyltransferase activity of the PRC2 complex, leading to a global reduction of H3K27 di- and trimethylation levels (H3K27me2 and H3K27me3)2. The H3.3K27M mutations are associated with the loss-of-function mutation in p53 and the amplification or gain-of-function mutations in PDGFRA (platelet-derived growth factor receptor), FGFR1 (fibroblast growth factor receptor), and other receptor tyrosine kinases3.

                            H3K36M

                            H3K36M (Figure 1) is the only recurrent mutation present in the vast majority of chondroblastomas and may act as an oncogenic driver in these tumors. Similar to H3K27M, the H3K36M mutation suppresses the methyltransferase activity of SETD2 and NSD family proteins and leads to the global reduction of H3K36 di- and trimethylation levels. Genome-wide ChIP-seq analyses suggest that K36M is a driver mutation that alters the epigenetic landscape and promotes neoplastic transformation in the chondrocyte lineage3.

                            H3G34 (W/V/R)

                            Histone mutations at H3G34 include substitutions of glycine 34 with tryptophan (G34W), arginine (G34R), or valine (G34V) (Figure 1). While H3G34W mutations are present at high frequency (>90%) in giant cell tumor of bone (GCTB), H3G34R/V mutations are predominantly found in high-grade gliomas of children and adolescents. In gliomas, H3.3G34R/V mutations are associated with loss-of-function mutations in the tumor suppressor gene p53 and ATP-dependent helicase ATRX, as well as with the deregulated expression of N-Myc protein4. In GCTB, H3.3G34W expression was shown to promote cellular proliferation in-vitro through inducing transcriptional deregulation and splicing alterations5. Furthermore, several studies indicate that replacement of H3G34 with any other amino acid residue blocks SETD2 binding and thereby may hinder methylation of H3K361. 

                            ​​​​​​​​​​​​​​​Figure 1. Histone H3 mutations and their associated cancer types.​​

                            Current research suggests that histone mutations alter the epigenetic landscape, but underlying mechanisms are not completely understood. The identification of widespread recurrent driver mutations in histones has raised significant interest in the development of novel targeted epigenetic therapies for histone mutant tumors, as well as biomarkers for diagnostics and monitoring of drug response.

                            If you are interested in histones and their modifications, check out our article on histone modifications and our poster on epigenetic modifications.

                            Tools to study your target​

                            We have developed recombinant monoclonal RabMAbs to the key histone H3 mutants to help you advance the field of histone mutants in cancer epigenetics.

                            Histone mutantDescription

                            H3K27M

                            ​

                            IHC of paraffin-embedded mouse brain tissue labeling H3K27M with ab190631 at 1/500 dilution followed by Discovery UltraMap anti-rabbit (HRP).

                            H3K27M is found in pediatric brain tumors (pHGG and DIPG), acute myeloid leukemia, melanoma, and glioma. Acts as a suppressor of PCR2 complex and impedes histone methylation.

                            Recommended Ab ID: ab190631


                            Applications: WB, Indirect ELISA, IHC-P, ICC/IF, IP, ChIP


                            Related targets: EZH2, SUZ12, EED, p53, PDFRA, FGFR1, ACVR1, BCOR, H3K27me2, H3K27me3

                            H3K36M

                            ​
                            ​IHC of paraffin-embedded human chondroblastoma tissue labeling H3K36M with ab256384 at 1/4000 dilution followed by a goat anti-rabbit IgG H&L (HRP).

                            H3K36M is a potential oncogenic driver mutation in chondroblastomas; also found in pediatric soft tissue sarcomas and HNSCC. Hinders histone methylation through suppressing SETD2 and NSD family of methyltransferases.

                            Recommended Ab ID: ab256384.


                            Applications: IP, WB, IHC-P, ICC/IF, Flow Cyt, Indirect ELISA.


                            Related targets: SETD2, NSD1, NSD2, H3K36me2, H3K36me3.

                            H3G34W

                            ​